Vaxart, Inc. (VXRT) — SEC-Verified Company Profile

Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary VAAST platform. The company's tablet vaccines use a non-replicating Ad5 vector to deliver antigens and adjuvants to the small intestine, targeting mucosal and systemic immunity. Pipeline candidates address norovirus, COVID-19, influenza, and HPV-related cervical cancer. No products are currently approved or marketed.

infectious-disease-vaccinesnorovirus-preventioncovid-19-preventioninfluenza-preventionhpv-related-cancer-therapeuticsmucosal-vaccine-deliverynon-replicating-adenovirus-type-5-(ad5)-vectortoll-like-receptor-3-(tlr3)-agonist-dsrna-adjuvantenteric-coated-tablet-delivery

Products

Name	Type	Description
Bivalent Norovirus Oral Tablet Vaccine Candidate	platform	VP1-based oral tablet vaccine targeting norovirus GI.1 and GII.4 strains, delivered to small intestine to induce mucosal and systemic immune responses.
COVID-19 Oral Tablet Vaccine Candidate	platform	Oral recombinant vaccine candidate targeting SARS-CoV-2 using the VAAST Ad5 vector platform.
Influenza Oral Tablet Vaccine Candidate	platform	Oral tablet vaccine candidate targeting influenza using the VAAST Ad5 vector platform.
HPV Therapeutic Vaccine Candidate	platform	Preclinical therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus.
VAAST Platform	platform	Proprietary oral vaccine platform using non-replicating Ad5 vector with dsRNA adjuvant delivered via enteric-coated tablet to the small intestine.

SEC Filings

View all SEC EDGAR filings: EDGAR Company Page

Structured filing index: /api/company/VXRT/filings

Origin — Data Provenance
This profile was extracted from SEC EDGAR filings (PEM-signed by sec.gov).
Every API response includes a cryptographic origin leaf for chain-of-custody tracking.
AI Discovery Document | Registry Metrics | GitHub